NCT07280299Phase 2Not yet recruiting

Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease

Study sponsor: Gain Therapeutics, Inc. · GANX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-06-30Estimated
Enrollment · participants111Estimated
Source updated2025-12-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.